Advertisement
Advertisement
MESO
Mesoblast Limited - ADR
14.27
USDSponsored
+0.17
+1.21%
Nov 06, 15:59 UTC -5
Closed
After-Market
14.27
0.00
-0.04%
Mesoblast Limited - ADR (MESO) Earnings
MESO Earnings Reports
Positive Surprise Ratio
MESO beat 9 of 12 last estimates.
75%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q2 27 (Revenue/ EPS)
$69.69M
/-$0.02
Implied change from Q4 26 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/-33.33%
Mesoblast Limited - ADR earnings per share and revenue
On Aug 26, 2026, MESO reported earnings of -- USD per share (EPS) for Q4 26, -- the estimate of -0.10 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 66.66 million, with a --% difference. The market reacted with a +7.96% price change (close before vs. close after earnings).
Looking ahead to Q2 27, 4 analysts forecast an EPS of -0.02 USD, with revenue projected to reach 69.69 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Mesoblast Limited - ADR's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Mesoblast Limited - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Mesoblast Limited - ADR's Q4 2026 earnings?
The stock price moved up 7.96%, changed from $16.84 before the earnings release to $18.18 the day after.
When is Mesoblast Limited - ADR expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Mesoblast Limited - ADR's next earnings report?
Based on 4
analysts, Mesoblast Limited - ADR is expected to report EPS of -$0.02 and revenue of $69.69M for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.